Latest EQL Pharma News & Updates

See the latest news and media coverage for EQL Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

EQL Pharma

Swedish generic pharmaceuticals developer and marketer

eqlpharma.com

Headquarters: Sweden
Company type: Public company
Number of employees: 10–60

Last updated Today

Latest news about EQL Pharma

In short: EQL Pharma reported record annual sales of SEK 120.2 million for Q4 2025/26 but faced a significant profit decline due to rising logistics costs.

Company announcements

May 8 EQL Pharma

EQL Pharma reports year-end results for April 2025–March 2026

Sales increased 6% to 120.2 MSEK in Q4, but margins fell due to one-off costs and logistics issues. Forecast for 2026/27 is 15% growth.

February 3 EQL Pharma

EQL Pharma's CEO presents Q3 FY 2025/26 results

EQL Pharma reports record quarter with 29% sales growth

Sales rose to 118.9 MSEK and EBITDA to 24.9 MSEK. A new product was launched and two management members were recruited. Forecast for the full year is 15% growth.

5 November 2025 EQL Pharma

EQL Pharma publishes half-year report April–September 2025

Sales increased 1% to 86.4 MSEK in Q2 due to delivery disruptions. EBITDA margin fell to 10%. Forecast for 2025/26: 15% growth and 20% EBITDA.

Media coverage

May 9 The Globe and Mail

EQL Pharma Delivers Record Sales but Margin Hit Forces Sharper Focus and Slower Pipeline

EQL Pharma reported record quarterly sales of SEK 120.2 million for the fourth quarter, up 6% year-on-year, but profitability weakened as gross margin fell to...

May 8 FinanzNachrichten

EQL Pharma AB: Year-end Report April 2025 - March 2026

During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year...

May 8 Dagens industri

Pharmaceutical company report plummets - CEO managed to sell millions before

The pharmaceutical company EQL Pharma plummets 37 percent on its report, where the operating profit decreased from 23 to 5.1 million kronor and...

March 25 FinanzNachrichten

EQL Pharma AB: Mellozzan (melatonin) has been approved in Italy

EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by...

Never miss news about EQL Pharma

Track EQL Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.